Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 4
1954 5
1955 1
1958 1
1959 1
1962 1
1964 1
1965 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 1
1973 1
1977 2
1978 2
1979 1
1980 1
1981 1
1984 4
1985 1
1986 6
1987 4
1988 2
1989 5
1990 8
1991 7
1992 6
1993 10
1994 1
1995 7
1996 2
1997 3
1998 2
1999 4
2000 3
2001 4
2002 5
2003 2
2004 6
2005 11
2006 11
2007 8
2008 5
2009 10
2010 2
2011 7
2012 9
2013 6
2014 8
2015 8
2016 17
2017 10
2018 8
2019 18
2020 12
2021 15
2022 19
2023 30
2024 28
2025 35
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
Multi-scale signaling and tumor evolution in high-grade gliomas.
Liu J, Cao S, Imbach KJ, Gritsenko MA, Lih TM, Kyle JE, Yaron-Barir TM, Binder ZA, Li Y, Strunilin I, Wang YT, Tsai CF, Ma W, Chen L, Clark NM, Shinkle A, Naser Al Deen N, Caravan W, Houston A, Simin FA, Wyczalkowski MA, Wang LB, Storrs E, Chen S, Illindala R, Li YD, Jayasinghe RG, Rykunov D, Cottingham SL, Chu RK, Weitz KK, Moore RJ, Sagendorf T, Petyuk VA, Nestor M, Bramer LM, Stratton KG, Schepmoes AA, Couvillion SP, Eder J, Kim YM, Gao Y, Fillmore TL, Zhao R, Monroe ME, Southard-Smith AN, Li YE, Jui-Hsien Lu R, Johnson JL, Wiznerowicz M, Hostetter G, Newton CJ, Ketchum KA, Thangudu RR, Barnholtz-Sloan JS, Wang P, Fenyö D, An E, Thiagarajan M, Robles AI, Mani DR, Smith RD, Porta-Pardo E, Cantley LC, Iavarone A, Chen F, Mesri M, Nasrallah MP, Zhang H, Resnick AC, Chheda MG, Rodland KD, Liu T, Ding L; Philadelphia Coalition for a Cure; Clinical Proteomic Tumor Analysis Consortium. Liu J, et al. Among authors: eder j. Cancer Cell. 2024 Jul 8;42(7):1217-1238.e19. doi: 10.1016/j.ccell.2024.06.004. Cancer Cell. 2024. PMID: 38981438 Free PMC article.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Garon EB, et al. Among authors: eder jp. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891174 Free article. Clinical Trial.
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J. Schubart A, et al. Among authors: eder j. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. doi: 10.1073/pnas.1820892116. Epub 2019 Mar 29. Proc Natl Acad Sci U S A. 2019. PMID: 30926668 Free PMC article.
Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification.
Gollmann-Tepeköylü C, Graber M, Hirsch J, Mair S, Naschberger A, Pölzl L, Nägele F, Kirchmair E, Degenhart G, Demetz E, Hilbe R, Chen HY, Engert JC, Böhm A, Franz N, Lobenwein D, Lener D, Fuchs C, Weihs A, Töchterle S, Vogel GF, Schweiger V, Eder J, Pietschmann P, Seifert M, Kronenberg F, Coassin S, Blumer M, Hackl H, Meyer D, Feuchtner G, Kirchmair R, Troppmair J, Krane M, Weiss G, Tsimikas S, Thanassoulis G, Grimm M, Rupp B, Huber LA, Zhang SY, Casanova JL, Tancevski I, Holfeld J. Gollmann-Tepeköylü C, et al. Among authors: eder j. Circulation. 2023 May 16;147(20):1518-1533. doi: 10.1161/CIRCULATIONAHA.122.063481. Epub 2023 Apr 4. Circulation. 2023. PMID: 37013819 Free PMC article.
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Garon EB, et al. Among authors: eder jp. J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2. J Clin Oncol. 2019. PMID: 31154919 Free PMC article. Clinical Trial.
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.
Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, McCormack P, Yu J, Huang X, Chiu YH, Chen Z, Schleeger S, Horny G, DiPetrillo K, Muller L, Hein A, Villard F, Scharenberg M, Ramage P, Hassiepen U, Côté S, DeGagne J, Krantz C, Eder J, Stoll B, Kulmatycki K, Feldman DL, Hoffmann P, Basson CT, Frost RJA, Khder Y. Koch AW, et al. Among authors: eder j. Blood. 2019 Mar 28;133(13):1507-1516. doi: 10.1182/blood-2018-10-880849. Epub 2019 Jan 28. Blood. 2019. PMID: 30692123 Free article.
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. Segal NH, et al. Among authors: eder jp. Nat Commun. 2024 May 15;15(1):4091. doi: 10.1038/s41467-024-48479-8. Nat Commun. 2024. PMID: 38750034 Free PMC article. Clinical Trial.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Seiwert TY, et al. Among authors: eder jp. Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27. Lancet Oncol. 2016. PMID: 27247226 Clinical Trial.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: eder jp. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
369 results